Abstract
AptarGroup will report second-quarter 2026 results on July 30, 2026 Post Market; this preview summarizes consensus expectations for revenue, margins, and adjusted EPS, and evaluates segment dynamics and analyst views for the upcoming print.Market Forecast
Consensus expects AptarGroup’s current quarter revenue at 1.01 billion US dollars, implying 5.47% year-over-year growth; the company’s forecast framework implies EPS of 1.35 and EBIT of 126.30 million US dollars with year-over-year changes of -13.37% and -11.16%, respectively. Margin assumptions embed a mixed picture: gross margin is modeled near the mid-30s and net profit margin trends are projected stable-to-lower, while adjusted EPS growth lags revenue due to rising operating costs and mix.Main business momentum is led by demand in core dispensing and drug delivery solutions, with revenue last quarter distributed across Pharmacy at 438.56 million US dollars, Beauty at 363.64 million US dollars, and Closures at 180.67 million US dollars, pointing to steady demand across end-markets. The most promising segment is Pharmacy, the largest revenue contributor, supported by resilient healthcare volumes and ongoing innovation in drug delivery formats.
Last Quarter Review
In the previous quarter, AptarGroup delivered revenue of 982.87 million US dollars, gross profit margin of 35.80%, GAAP net profit attributable to shareholders of 72.67 million US dollars with a net profit margin of 7.39%, and adjusted EPS of 1.19, with year-over-year revenue growth of 10.77% and a modest EPS decline of 0.83%. A key highlight was a revenue beat versus market estimates alongside EBIT outperformance, underpinned by resilient demand and improved operational execution. By business, Pharmacy generated 438.56 million US dollars, Beauty 363.64 million US dollars, and Closures 180.67 million US dollars, indicating balanced growth across segments.Current Quarter Outlook
Main business dynamics
AptarGroup’s core operations continue to benefit from stable demand in dispensing and sealing solutions across consumer and healthcare end-markets. The current quarter revenue outlook of 1.01 billion US dollars signals continued top-line expansion, aided by price discipline and product innovation. However, EBIT and EPS forecasts suggest pressure from cost inflation and mix, which may partially offset volume gains, keeping a lid on earnings leverage this quarter.The margin trajectory will be a focal point. With gross margin previously at 35.80%, even modest cost headwinds in resins, freight, or energy could squeeze profitability if mix skews toward lower-margin categories. Management’s ongoing productivity initiatives and pricing actions should help defend margins, but investors will watch whether conversion of revenue growth into profit improves compared to last quarter. Any signs that pricing continues to offset input costs would be supportive for near-term sentiment.
Cash generation and capital deployment are secondary supports for the equity story in the near term. Historically, AptarGroup has balanced reinvestment with disciplined returns. An update on free cash flow conversion and any incremental commentary on capex for high-growth platforms would inform sustainability of earnings power into the back half of the year.
Most promising segment: Pharmacy
Pharmacy remains the largest revenue contributor and appears positioned for durable growth. The prior quarter’s 438.56 million US dollars from the Pharmacy business underscores robust demand for drug delivery and packaging solutions that often hold higher switching costs and stickier customer relationships than consumer-facing categories. The company’s innovation pipeline in inhalation, nasal, and injectable delivery formats can drive mix upgrade over time.For this quarter, the setup favors continued resilience in Pharmacy volumes, supported by healthcare end-market stability. While the aggregate EPS forecast is below last year, a steadier Pharmacy margin profile could cushion the consolidated margin. Any evidence of new program ramps or better-than-expected order patterns would be an upside risk to consensus EBIT. Conversely, if mix shifts toward lower-complexity solutions, segment margin progression could be slower than investors expect.
Investors will monitor order visibility and backlog quality. With regulatory cycles and customer validations often stretching timelines, updates on pipeline conversion and long-term supply agreements could strengthen confidence in medium-term growth. Clear commentary on pricing recovery in healthcare contracts would further support the bull thesis on Pharmacy.
Key stock price swing factors this quarter
Margin conversion versus revenue growth is likely to be the main swing factor. Consensus anticipates revenue growth of 5.47% year over year, but forecasts EPS down 13.37%, implying deleverage from mix or cost inflation. If AptarGroup demonstrates better expense control, procurement savings, or product mix uplift, the gap between revenue and EPS growth could narrow, leading to positive estimate revisions.Segment mix is the second major factor. Outperformance in Pharmacy would generally support higher margins and investor sentiment, while an outsized contribution from lower-margin consumer closures could cap upside. Management’s commentary on product launches in higher-value drug delivery systems will be closely watched for implications on gross margin trajectory. Additionally, demand conditions in Beauty and Closures will influence top-line variability, especially if retailers adjust inventories or promotional intensity shifts.
Finally, cash flow and guidance cadence can sway near-term trading. A reaffirmation or upgrade to full-year revenue or EPS framework would likely be taken positively, particularly if paired with evidence of improved working capital efficiency. Conversely, any cautious commentary on second-half demand or incremental cost pressures could reinforce the current conservative EPS forecast and weigh on shares.
Analyst Opinions
Bullish views appear to dominate recent commentary on AptarGroup, focusing on steady healthcare-driven growth and improving operational execution despite a softer EPS trajectory. Institutions highlight the company’s durable positioning in drug delivery solutions and the likelihood that pricing and productivity actions will protect margins as revenue grows. Analysts also emphasize the potential for Pharmacy-led upside if innovation programs and customer wins accelerate through the year, which could produce positive operating leverage relative to current forecasts.Several well-known brokerages have noted that AptarGroup’s balance between consumer and healthcare exposures offers defensive characteristics, with the Pharmacy segment anchoring stability and the Beauty and Closures businesses providing additional volume recovery optionality. The majority stance expects the company to meet or slightly exceed revenue guidance while working through near-term earnings headwinds, with a constructive bias into the back half if mix improves. Overall, analyst consensus skews positive on the setup for the current quarter, centered on resilient healthcare demand and disciplined execution.
Comments